Please Wait
Applying Filters...
menu
    • menu
    TransoPharm USA works in the Sourcing and Management of Active Pharmaceutical Ingredients.

    Virtual Booth

    Contact Supplier

    Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

    Virtual Booth

    Contact Supplier

    dmfs-not-supported-m-2025-06-30

    Virtual Booth

    An Enquiry

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Athena Pharmaceutiques is a Partner of Choice for Drug Delivery & Life Cycle Management.

    Virtual Booth

    Contact Supplier

    jdmfs-not-supported-m-2025-06-30

    Virtual Booth

    An Enquiry

    Menu

    Annamycin

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Moleculin Reports Positive Ph1B/2 Data for Annamycin in STS Lung
    Moleculin Reports Positive Ph1B/2 Data for Annamycin in STS Lung

    04 Jun 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/06/04/3093575/0/en/Moleculin-Reports-Positive-Topline-Efficacy-Results-from-U-S-Phase-1B-2-Clinical-Trial-Evaluating-Annamycin-for-the-Treatment-of-Soft-Tissue-Sarcoma-Lung-Metastases-MB-107.html

    GLOBENEWSWIRE
    04 Jun 2025
    Share Share
    WHO Approves Naxtarubicin As INN For Annamycin
    WHO Approves Naxtarubicin As INN For Annamycin

    06 May 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/05/06/3075142/0/en/Moleculin-Announces-World-Health-Organization-Approval-of-naxtarubicin-as-International-Non-Proprietary-Name-for-Annamycin.html

    GLOBENEWSWIRE
    06 May 2025
    Share Share
    Ascendis Share Endocrinology Rare Disease Data at ESPE & ESE 2O25
    Ascendis Share Endocrinology Rare Disease Data at ESPE & ESE 2O25

    05 May 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/05/05/3074063/0/en/Ascendis-to-Share-Its-Latest-Endocrinology-Rare-Disease-Data-at-ESPE-ESE-2025.html

    GLOBENEWSWIRE
    05 May 2025
    Share Share
    Moleculin's Annamycin Shows Promise in Pancreatic Cancer
    Moleculin's Annamycin Shows Promise in Pancreatic Cancer

    29 Apr 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/04/29/3070231/0/en/Moleculin-Announces-New-Pre-Clinical-Data-for-Annamycin-Demonstrating-Market-Expansion-Potential-Including-Treatment-for-Pancreatic-Cancer.html

    GLOBENEWSWIRE
    29 Apr 2025
    Share Share
    Moleculin Enhances Global Exclusivity with More Annamycin Patents
    Moleculin Enhances Global Exclusivity with More Annamycin Patents

    06 Mar 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/moleculin-announces-additional-annamycin-patent-allowances-to-enhance-global-exclusivity-302393600.html

    PR NEWSWIRE
    06 Mar 2025
    Share Share
    Moleculin Gets EU Nod To Recruit For MIRACLE Ph3 AML Trial
    Moleculin Gets EU Nod To Recruit For MIRACLE Ph3 AML Trial

    11 Feb 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/moleculin-receives-first-country-approval-in-europe-to-begin-recruiting-for-the-miracle-phase-3-rr-acute-myeloid-leukemia-aml-pivotal-trial-302372939.html

    PR NEWSWIRE
    11 Feb 2025
    Share Share